Mereo BioPharma(US:MREO) TMX Newsfile·2026-02-08 18:26Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Mereo BioPharma Group plc for alleged violations of federal securities laws related to misleading statements about its clinical programs [4]. Group 1: Legal Investigation - The law firm is encouraging Mereo investors who suffered losses exceeding $50,000 to contact them for discussing legal options [1]. - A federal securities class action has been filed against Mereo, with a deadline of April 6, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Mereo and its executives made false statements and failed to disclose the true state of the Phase 3 ORBIT and COSMIC programs, which did not meet their primary endpoints [4]. Group 2: Firm Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. - The firm has offices in New York, Pennsylvania, California, and Georgia, indicating a broad operational reach [3]. Group 3: Whistleblower Encouragement - The firm is also seeking information from whistleblowers, former employees, shareholders, and others regarding Mereo BioPharma's conduct [6].